Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Valeo Financial Advisors LLC increased its position in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 11.3% in the fourth quarter, according to the company in its most recent Form 13F filing with ...

Shares of Edwards Lifesciences Corp. rallied 6.92% to $75.82 Wednesday, on what proved to be an all-around grim trading ...

We regret to report that long term Edwards Lifesciences Corporation (NYSE:EW) shareholders have had that experience, with the share price dropping 28% in three years, versus a market return of ...

Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in ...

Barclays analyst Matt Miksic raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $88 and keeps an Overweight rating on the ...

Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $71 from $66 and keeps a Hold rating on the shares. The firm said they ...

Bleakley Financial Group LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 5.3% during the 4th ...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...